Please assess the completion status of the following clinical trial:

Trial Title: Safety and Immunogenicity Study of BCG, H4:IC31, and H56:IC31 Revaccination in Healthy Adolescents

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~1. Age of 12 to ≤ 17 years at enrollment~2. Minimum weight ≥ 40 kg~3. Previous BCG vaccination at least 5 years ago documented by scarification or medical card~4. No evidence of active TB disease, as determined by history, physical examination and, if deemed appropriate, sputum investigation and / or chest x-ray.~5. Negative QFT-GIT test at screening, using the manufacturer's recommended threshold of 0.35 IU/mL~6. Assessed by the clinic staff as being at low risk for HIV infection~7. Hemoglobin ≥ 11.7 g/dL for females, ≥ 12.5 g/dL for males~8. Negative HIV-1 and -2 blood test~9. Agree to consistently use effective contraception for sexual activity that could lead to pregnancy from at least 20 days prior to enrollment through the last required protocol clinic visit.~(additional minor criteria not added due to space constraints)~Exclusion Criteria:~1. Blood products received within 120 days before first vaccination~2. Investigational research agents received within 182 days before first vaccination~3. Intent to participate in another study of an investigational research agent during the planned duration of the HVTN 602 / AERAS A-042 study~4. Pregnant or breastfeeding~5. History of alcohol or drug abuse~6. A significant contact with active TB disease: for example, shared residency with an individual receiving anti-TB treatment, or with an individual known to have incompletely treated culture or smear positive TB~7. TB prophylaxis within 90 days prior to enrollment~8. History of treatment for active TB disease or latent Mtb infection~9. Positive and indeterminate QFT-GIT result~10. Received a tuberculin skin test (TST) within 90 days prior to enrollment~11. Vaccines and other Injections~12. Immunosuppressive medications received within 168 days before first vaccination.~13. Serious adverse reactions to vaccines including history of anaphylaxis and related symptoms such as hives, respiratory difficulty, angioedema, and/or abdominal pain.~14. Immunoglobulin received within 60 days before first vaccination~15. Autoimmune disease Not excluded: mild, well-controlled psoriasis~16. Clinically significant medical condition, physical examination findings, clinically significant abnormal laboratory results, or past medical history with clinically significant implications for current health. Including but not limited to: Diabetes mellitus type 1 or type 2, Thyroidectomy, or Thyroid disease, Asthma, Asplenia, Bleeding disorders, malignancy, Seizure disorder, and Angioedema~(additional minor criteria not added due to space constraints)

- Gender: ALL
- Minimum Age: 12 Years
- Maximum Age: 17 Years
- Healthy Volunteers: t

Study Arms:
- Group 1 H4:IC31 (Type: EXPERIMENTAL): 15 mcg H4/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
- Group 2 H56:IC31 (Type: EXPERIMENTAL): 5 mcg H56/500 nmol IC31 administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.
- Group 3 BCG (2-8 x 105 CFU) (Type: ACTIVE_COMPARATOR): Administered IM as 0.1 mL in either deltoid muscle at Day 0.
- Group 4 Control Sodium Chloride 0.9% (Type: PLACEBO_COMPARATOR): Administered IM as 0.5 mL in alternating deltoid muscle at Days 0 and 56.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete